MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
3.440
-0.060
-1.71%
After Hours: 3.440 0 0.00% 17:30 11/20 EST
OPEN
3.440
PREV CLOSE
3.500
HIGH
3.545
LOW
3.400
VOLUME
2.19M
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
2.342
MARKET CAP
545.63M
P/E (TTM)
-5.8315
1D
5D
1M
3M
1Y
5Y
1D
Aclaris Advances Modzatinib Trial in Lichen Planus: What ACRS Investors Should Know
TipRanks · 2d ago
Aclaris Therapeutics (ACRS) Gets a Buy from Leerink Partners
TipRanks · 3d ago
Aclaris Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 3d ago
Aclaris Therapeutics Price Target Cut to $12.00/Share From $13.00 by Canaccord Genuity
Dow Jones · 3d ago
Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12
Benzinga · 3d ago
This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Benzinga · 3d ago
Aclaris Therapeutics Cut to Neutral From Outperform by Wedbush
Dow Jones · 3d ago
Aclaris Therapeutics Price Target Cut to $3.00/Share From $8.00 by Wedbush
Dow Jones · 3d ago
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.